In this context, a vast array of PDE inhibitors with different selectivities have been developed, although, in practice, the number of PDE-targeting drugs that have reached the market is relatively limited and circumscribed to COPD, inflammatory skin diseases and cardiovascular diseases [93]. Here, ALDH7A1 is linked to cardiovascular disorder.